Quantum-Si Incorporated Announces $50 Million Registered Direct Offering to Accelerate Growth in Proteomics Technology
Quantum-Si Incorporated (Nasdaq: QSI), a pioneering proteomics technology company revolutionizing protein analysis through single-molecule detection, has announced a significant financial milestone. The company has entered into a securities purchase agreement with a single institutional investor for the sale of 29,940,119 shares of its common stock (and common stock equivalents) at a purchase price of $1.67 per share. This registered direct offering is expected to generate gross proceeds of approximately $50 million before accounting for placement agent commissions and other related expenses. The transaction is anticipated to close on or around July 8, 2025, subject to the fulfillment of customary closing conditions.
Strengthening Financial Position for Future Growth
The proceeds from this offering will be allocated toward working capital and general corporate purposes, enabling Quantum-Si to further advance its mission of redefining protein analysis through cutting-edge innovation. As a leader in the field of proteomics, Quantum-Si’s groundbreaking single-molecule detection technology has positioned the company at the forefront of scientific discovery. By leveraging the funds raised, the company aims to expand its research and development efforts, enhance its product offerings, and strengthen its competitive edge in the rapidly evolving biotechnology landscape.
This strategic move underscores Quantum-Si’s commitment to delivering transformative solutions that address unmet needs in protein analysis. The additional capital will provide the company with the flexibility to pursue new opportunities, invest in key initiatives, and continue driving value for its shareholders.
A.G.P./Alliance Global Partners as Placement Agent
A.G.P./Alliance Global Partners is serving as the sole placement agent for the offering. With its deep expertise in capital markets and extensive network, A.G.P. has played a pivotal role in facilitating this transaction. Their involvement highlights the confidence institutional investors have in Quantum-Si’s vision and potential for long-term success.
Regulatory Framework and Prospectus Availability
The offering is being conducted pursuant to an effective shelf registration statement on Form S-3 (File No. 333-273934), which was declared effective by the Securities and Exchange Commission (SEC) on August 22, 2023. The securities are being offered exclusively through a prospectus, which forms part of the registration statement. A final prospectus supplement and the accompanying base prospectus relating to the offering will be filed with the SEC and made available on its official website at http://www.sec.gov.
Interested parties can also obtain electronic copies of these documents, when available, directly from A.G.P./Alliance Global Partners. Requests can be made via telephone at (212) 624-2060, email at prospectus@allianceg.com, or by contacting the firm at their New York office located at 590 Madison Avenue, 28th Floor, New York, NY 10022.
Legal Disclaimer
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities described herein. Furthermore, no sale of these securities will occur in any state or jurisdiction where such an offer, solicitation, or sale would violate applicable securities laws. All transactions are subject to compliance with regulatory requirements, ensuring transparency and adherence to legal standards.
Advancing Proteomics Innovation Through Strategic Financing
Quantum-Si’s decision to raise $50 million through this registered direct offering reflects its proactive approach to securing the resources necessary to fuel growth and innovation. The company’s proprietary single-molecule detection platform has already demonstrated its potential to unlock new insights into biology and medicine. By analyzing proteins at unprecedented levels of detail, Quantum-Si is empowering researchers and clinicians to better understand disease mechanisms, develop targeted therapies, and improve patient outcomes.
With the proceeds from this offering, Quantum-Si is well-positioned to accelerate its product development pipeline, scale manufacturing capabilities, and expand its commercial footprint. These efforts will not only reinforce the company’s leadership in proteomics but also solidify its reputation as a trusted partner in advancing scientific discovery.
About Quantum-Si Incorporated
Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live.
